← Eichor
Condition: Braf Gene Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Braf Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
Phase N/A · 13 location(s) · Swiss Cancer Institute · NCT07617610A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NA · 45 location(s) · UNICANCER · NCT05639413XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06902376Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
Phase 2 · 1 location(s) · Eva Marie Erfurth, MD, PhD · NCT05525273Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
EARLY_Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04741997Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
Phase 1 · 13 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT06536400Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-
Phase N/A · 8 location(s) · Novartis Pharmaceuticals · NCT05868629Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224815Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
Phase N/A · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06449989Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06653517Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Phase 1 · 4 location(s) · Rina Plattner · NCT04903119DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Phase N/A · 1 location(s) · Fudan University · NCT06749015Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06763029Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
Phase 1 · 6 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07158710BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
Phase N/A · 70 location(s) · Pierre Fabre Pharma GmbH · NCT04673955A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06610682Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT03975231A Study of DEG6498 in Participants With Solid Tumors
Phase 1 · 3 location(s) · Degron Therapeutics Co. · NCT07244835Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224841Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT03042221Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT05800340PAS-004 in Patients With Advanced Solid Tumors
Phase 1 · 7 location(s) · Pasithea Therapeutics Corp. · NCT06299839DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05722886Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Phase 2 · 7 location(s) · University of California, San Francisco · NCT07110246Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cance
Phase 2 · 1 location(s) · Federation Francophone de Cancerologie Digestive · NCT05706779Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
Phase 1 · 2 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07561554Special Drug Use-results Surveillance of Tafinlar/Mekinist
Phase N/A · 70 location(s) · Novartis Pharmaceuticals · NCT06262919
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.